Precision medicine developer Matchpoint Therapeutics has landed $150.0M in Series b funding, bringing a significant boost to its work on immune diseases and other serious illnesses. The biotechnology company specializes in discovering precision covalent medicines, leveraging its proprietary Advanced Covalent Exploration (ACE) platform which integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution.
The round drew investment from a broad syndicate including Nextech Invest, Norwest, Invus, BB Biotech, T1D Fund, BOLD Longevity Growth, Access Biotechnology, Atlas Venture, Sanofi Ventures, and Digitalis Ventures, as Matchpoint continues to build an emerging pipeline of novel covalent medicines initially focused on immunology.


















